3 traits to look for in an oncology real-world data partner
Before raw, real-world data (RWD) can be transformed into actionable insights, it has to go through a number of different processes, from aggregation and abstraction to standardization and careful curation.
For the hematology community, AI and RWD are top of mind
A huge number of new breakthroughs in drug development, treatment guidelines, and decision support technologies occur every day to treat blood cancers.
LLMs aren’t good enough at diagnostics yet. What will it take to get them there?
Large language models (LLMs) are the foundation of highly hyped generative AI tools like Chat-GPT and Google Bard.
What’s in store for 2024? Generative AI, digital health funding, and real-world data
To ring in the new year, we asked COTA’s leadership team about their top predictions for 2024 in the oncology, real-world data, and life sciences spaces.
Women in Health Innovation: Deloitte x COTA blog series
In our blog series with Deloitte, we have written extensively about the benefits of using Real World Data to enhance clinical trials and accelerate research into new therapies for a variety of conditions.
COTA and Aetion partner to expand access to real-world data for oncology research
This collaboration enables Aetion and COTA to meet the needs of researchers requiring high-quality, clinically rich oncology data, for both liquid and solid tumor types.
Overcoming challenges to integrating biomarker data into clinical trials
Life sciences researchers and oncologists are learning more about cancer pathogenesis and treatment every day, largely thanks to explosive innovation in the world of biomarkers.
How to use real-world clinicogenomic data to fuel drug development
This blog series talks extensively about the benefits of using real-world data (RWD) to enhance clinical trials and accelerate research into new therapies for a variety of different conditions. Now it’s time to take a closer look at the details.
Enriching access to multimodal data insights with COTA Connect
Today, COTA is introducing COTA Connect: a powerful new capability to link data with a variety of different supplemental data sources, including linking COTA’s robust real-world clinical data to claims, imaging, socioeconomic data, and more.
So you want to train an oncology LLM: Start by getting close to the data
To create targeted LLMs that are suitable for diving into health-related areas like oncology, we must choose our data carefully and get as close to the original source as possible to avoid “playing telephone” with inaccurate information that could affect drug development processes or cancer outcomes.
